Skip to Content
Merck
  • Prokaryotic NavMs channel as a structural and functional model for eukaryotic sodium channel antagonism.

Prokaryotic NavMs channel as a structural and functional model for eukaryotic sodium channel antagonism.

Proceedings of the National Academy of Sciences of the United States of America (2014-05-23)
Claire Bagnéris, Paul G DeCaen, Claire E Naylor, David C Pryde, Irene Nobeli, David E Clapham, B A Wallace
ABSTRACT

Voltage-gated sodium channels are important targets for the development of pharmaceutical drugs, because mutations in different human sodium channel isoforms have causal relationships with a range of neurological and cardiovascular diseases. In this study, functional electrophysiological studies show that the prokaryotic sodium channel from Magnetococcus marinus (NavMs) binds and is inhibited by eukaryotic sodium channel blockers in a manner similar to the human Nav1.1 channel, despite millions of years of divergent evolution between the two types of channels. Crystal complexes of the NavMs pore with several brominated blocker compounds depict a common antagonist binding site in the cavity, adjacent to lipid-facing fenestrations proposed to be the portals for drug entry. In silico docking studies indicate the full extent of the blocker binding site, and electrophysiology studies of NavMs channels with mutations at adjacent residues validate the location. These results suggest that the NavMs channel can be a valuable tool for screening and rational design of human drugs.

MATERIALS
Product Number
Brand
Product Description

Lidocaine, European Pharmacopoeia (EP) Reference Standard
Supelco
Lidocaine, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Propylamine, analytical standard
USP
Lidocaine, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Lidocaine, analytical standard
Sigma-Aldrich
Lidocaine, powder
Sigma-Aldrich
Propylamine, ≥99%
Sigma-Aldrich
Propylamine, 98%
Sigma-Aldrich
Propylamine, purum, ≥99.0% (GC)
Sigma-Aldrich
2-Amino-6-bromobenzothiazole, 97%
Sigma-Aldrich
Lamotrigine, ≥98%, powder
Sigma-Aldrich
Thallium(I) nitrate, 99.9% trace metals basis
Sigma-Aldrich
Thallium(I) nitrate, 99.999% trace metals basis
Supelco
Lamotrigine, Pharmaceutical Secondary Standard; Certified Reference Material
Lamotrigine for system suitability, European Pharmacopoeia (EP) Reference Standard
Lamotrigine for peak identification, European Pharmacopoeia (EP) Reference Standard
Lamotrigine, European Pharmacopoeia (EP) Reference Standard
USP
Lamotrigine, United States Pharmacopeia (USP) Reference Standard